ImmunityBio's stock has been influenced by several events over the past six months (May 2026 - November 2026). On November 5, 2026, the first patients in Europe received ANKTIVA treatment, though the stock moved below its 50-day moving average and Momentum Indicator, signaling bearish trends. In October 2026, the FDA expanded ANKTIVA's approval to include papillary-only BCG-unresponsive non-muscle invasive bladder cancer. On October 28, 2026, the 10-day moving average crossed bearishly below the 50-day moving average. ImmunityBio announced Q2 2026 earnings on August 4, 2026, reporting record net product revenue of $50.7 million, a 92% increase year-over-year and the eighth consecutive quarter of sequential revenue growth. In July 2026, the United Arab Emirates granted marketing authorization for ANKTIVA across BCG-unresponsive NMIBC and metastatic NSCLC. On March 31, 2026, the company secured $75 million in non-dilutive financing and reduced debt by $25 million through a conversion by Nant Capital. A securities fraud investigation was announced on March 30, 2026, following a Bloomberg report on March 24, 2026, about an FDA Warning Letter regarding inaccurate claims made by the Executive Chairman about ANKTIVA on a podcast, which caused a 21.12% stock price fall. The stock jumped 40% on February 19, 2026, due to positive regulatory and clinical updates, including European conditional marketing authorization for ANKTIVA and new Phase 2 trials for CAR-NK cell therapy programs. However, on February 13, 2026, the stock dropped 10.2% after a law firm announced an investigation into potential securities fraud. In February 2026, the European Commission granted conditional marketing authorization for ANKTIVA. On February 23, 2026, the company reported full-year 2025 financial and operational highlights, including approximately $113 million in net product revenue for ANKTIVA (a 700% increase year-over-year) and an expanded global regulatory footprint to 33 countries. In January 2026, the Saudi Food and Drug Authority (SFDA) granted accelerated approval for ANKTIVA in BCG-unresponsive NMIBC CIS and conditional accelerated approval for metastatic NSCLC.